Skip to search formSkip to main contentSkip to account menu

monoclonal antibody MX35 F(ab')2

Known as: MX35 F(ab')2, MX35 F(ab')2 monoclonal antibody, MoAb MX35 F(ab')2 
The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
CD3 Ligation on Immature Thymocytes Generates Antagonist-like Signals Appropriate for CD8 Lineage Commitment, Independently of  T Cell Receptor Specificity
The signals that direct differentiation of T cells to the CD4 or CD8 lineages in the thymus remain poorly understood. Although it… 
Highly Cited
1996
Highly Cited
1996
Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha M beta 2' CD11b/CD18) during neutrophil polarization.
Previous studies have shown that the leukocyte integrin CR3 (CD11b/CD18) is physically associated with the urokinase-type… 
Highly Cited
1995
Highly Cited
1995
Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional…
BACKGROUND A murine monoclonal antibody designated Z2D3 (IgM) generated against homogenized human atherosclerotic plaques was… 
Highly Cited
1994
Highly Cited
1994
Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes.
A previous study has shown that Fc gamma RIIIB (CD16), an extensively glycosylated glycosyl-phosphatidylinositol-linked… 
Highly Cited
1994
Highly Cited
1994
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
In a phase I trial the toxicity and immunomodulatory effects of combined treatment with intravenous (i.v.) bispecific monoclonal… 
Highly Cited
1993
Highly Cited
1993
Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
A detailed technical protocol is provided for reproducible and aseptical production of stable 186Re-monoclonal antibody… 
Highly Cited
1992
Highly Cited
1992
Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
Rhenium is a radionuclide with physical and chemical properties suitable for radioimmunotherapy. Two Phase I trials were carried… 
Highly Cited
1991
Highly Cited
1991
Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
A bispecific F(ab')2 fragment with anti-CD3 and antitumor specificity was used to target activated human peripheral blood… 
Highly Cited
1984
Highly Cited
1984
Regulation of T-cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies.
Eight mouse monoclonal antibodies specific for hepatitis B surface antigen (HBsAg) were examined for their effects on the antigen… 
Highly Cited
1981
Highly Cited
1981
A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma.
The antigen of a monoclonal antibody that is specific for cells of human carcinoma of the colon is a monosialoganglioside as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)